Johnson & Johnson MedTech today announced new data confirming the benefits of its Abiomed business' Impella CP system.

A Japanese registry study reveals how DanGer shock criteria predict survival in heart attack patients treated with Impella.

Air Evac Lifeteam members Arianne Emling and Beau McFarlin are set to receive the prestigious Stars of Life award in ...

The artificial intelligence (AI)-based risk tool GRACE 3.0 may better identify patients with non-ST-elevation acute coronary ...

More Impella left-sided blood pumps are under Class I recall, this time for potential interactions with transcatheter aortic valve replacement (TAVR) stents, the FDA announced Thursday. The affected ...

The Food and Drug Administration has identified a Class I recall of Abiomed Automated Impella Controllers due to the ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

There are new and revised warnings about the instructions for use of a certain type of heart pump that could lead to a risk of heart perforation, according to an alert issued by the pump's ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...

Large-bore devices and longer time on support each up the risk. A study author calls for awareness, not alarm.

Use of a microaxial flow pump (Impella CP) with standard care led to a lower risk for death than standard care alone in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic ...

While no patients have been harmed, the FDA categorized the action as a Class I recall because of the potential for serious ...